The stock last traded at $54.99 significantly above $47.06, the 50 day moving average and which is significantly above the 200 day moving average of $38.47. The 50 day moving average was up $7.93 whereas the 200 day moving average was up $16.52 or +42.93%. (NASDAQ:EXAS) shares saw heavy trading volume with 6,502K shares changing hands by the end of trading on Tuesday. Shares saw a steep increase in trading volume of 283.04% over the normal average daily volume.
Investors are feeling more bullish on Exact Sciences Corporation as inferred by the change in short interest. The stock realized a fall in short interest between September 29, 2017 and October 13, 2017 of -2.54%. Short shares decreased 278,783 over that timeframe. Days to cover increased 1.0 to 7.0 and the short interest percentage is 0.09% as of October 13.
Additionally, here are a few investment firms who have increased or decreased their stake in (EXAS). Raymond James Financial Services Advisors, Inc. added to its stake by buying 19,014 shares an increase of 97.4%. Raymond James Financial Services Advisors, Inc. owns 38,535 shares valued at $1,816,000. The total value of its holdings increased 163.2%. As of the end of the quarter Simplex Trading, LLC had sold 4,789 shares trimming its stake by 51.4%. The value of the total investment in Exact Sciences Corporation went from $329,000 to $213,000 a change of 35.3% for the reporting period.
As of quarter end Affinity Investment Advisors, LLC had disposed of a total of 1,223 shares trimming its position 10.9%. The value of the company’s investment in Exact Sciences Corporation increased from $396,000 to $471,000 increasing 18.9% quarter over quarter. Ifc Holdings Incorporated/fl augmented its ownership by buying 5,762 shares an increase of 20.0% from 06/30/2017 to 09/30/2017. Ifc Holdings Incorporated/fl currently owns 34,575 shares worth $1,632,000. The value of the position overall is up by 60.5%.
July 20 investment analysts at Canaccord Genuity kept the stock rating at “Buy” and raised the price expectation to $42.00 from $26.00. On October 3 Canaccord Genuity maintained a company rating of “Buy” but raised the price expectation from $42.00 to $60.00.
As of the latest earnings report the EPS was $-1.29 and is expected to be $-1.17 for the current year with 119,096,000 shares now outstanding. Next quarter’s EPS is forecasted to be $-0.25 and the next full year EPS is projected to be $-0.71.
Exact Sciences Corporation, launched on February 10, 1995, is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. The Company offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer..